Newsletter Signup
Where current and emerging technology trends meet.
TecTrendsInformation Sources, Inc.
  | About TecTrends | Email Signup | Contact Us
 Live Search:
Live Search | Articles | Companies | TecTerms | Products
  Loading TecTrends Live Search - please wait... 
View Noteworthy Articles      PRNewswire
 
Company

Eisai Co Ltd Products   
4-6-10 Koishikawa, Bunkyo-ku
Tokyo,  JP  112-8088
Japan
Telephone: 81-3-3817-3700
URL: http://www.eisai.co.jp
Email: info@eisai.co.jp

Eisai Company Limited, established in 1941 and based in Tokyo, Japan, manufactures and markets pharmaceutical and over-the-counter (OTC) drugs and pharmaceutical production systems. The firm introduced its Neophyllin cardiotonic drug in 1950, the Sampoon contraceptive and Juvela vitamins in 1951, and the Methaphyllin ulcer tablets in 1953. In the 1960s and 1970s, the company introduced the Juvela Nicotinate microcirculation activator and Neuquinon metabolic cardiotonic drug products. The firm began marketing the Selbex gastritis and ulcer drug in 1984 and the Azeptin allergy treatment in 1986. The Glakay osteoporosis and Aricept (R) Alzheimer's disease treatments were introduced in 1995. Eisai also is known for the Chocola (R), Sacolon (R), and Nabolin (R) OTC drugs. Eisai maintains production facilities across Asia and the United States. It has 63 subsidiaries across Asia, Europe, and North America. Eisai was listed on the Tokyo and Osaka stock exchanges in 1961. The firm was founded as Sakuragaoka Research Laboratory by Toyoji Naito.

Org. Type: Corporation Equity Type: Public
Company Status: Active Date Founded: 1941
Symbol: TSE:4523

Products:
ARICEPT

TecTerms:
 


Home About TecTrends About Us Contact Us Privacy Statement Terms and Conditions

TecTrends | P.O. Box 8120 | Berkeley CA 94707 | (510) 525-6220 | Email: tectrends@tectrends.com
© 2006 INFORMATION SOURCES INC | All rights reserved.